|Bid||0.00 x 1000|
|Ask||0.00 x 900|
|Day's Range||84.88 - 84.98|
|52 Week Range||26.93 - 84.98|
|Beta (5Y Monthly)||1.09|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 22, 2020 - Apr 26, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||86.67|
Novartis and Britain's National Health Service (NHS) on Monday announced a pact that will clear the way for accelerated review by the country's health watchdog NICE for heart drug inclisiran, which could make it broadly available as soon as 2021. Novartis hopes the NHS deal will boost sales of cholesterol-lowering inclisiran, which the Swiss drugmaker bought in a deal announced last year for nearly $10 billion (£7.70 billion) and predicts will be a top seller. Inclisiran was submitted to U.S. regulators last year, and Novartis expects a European submission in coming weeks.
S&P; Dow Jones Indices will make the following changes to the S&P; SmallCap 600 effective prior to the open of trading on Monday, January 6:
Hedge funds and other investment firms that we track manage billions of dollars of their wealthy clients' money, and needless to say, they are painstakingly thorough when analyzing where to invest this money, as their own wealth also depends on it. Regardless of the various methods used by elite investors like David Tepper and David […]
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Cision, Ltd. (CISN) in connection with the proposed acquisition of the Company by an affiliate of Platinum Equity. Under the terms of the acquisition agreement, CISN shareholders will receive $10.00 in cash for each CISN share that they own.
Alnylam (ALNY) reports positive top-line results from the phase III study on lumasiran for the treatment of primary hyperoxaluria type 1.
Two of the industry’s leading gene-editing experts have unveiled their next venture: a gene-silencing startup called Triplet Therapeutics.
Mergers and acquisitions have lit up biotech stocks, and the hot pace shows no sign of slowing in 2020. Gene therapy and oncology companies are targets.
WILMINGTON, Del., Dec. 10, 2019 -- Rigrodsky & Long, P.A. announces that it is investigating: Audentes Therapeutics, Inc. (NASDAQ GS: BOLD) regarding possible breaches of.
BALA CYNWYD, PA / ACCESSWIRE / December 10, 2019 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of The Medicines Company ("TMC" or "the Company") (MDCO) for possible breaches of fiduciary duty and other violations of federal and state law in connection with proposed acquisition of the Company by Novartis AG. Under the terms of the agreement, TMC shareholders will receive only $85.00 for each share of TMC common stock owned. The investigation concerns whether the TMC Board breached its fiduciary duties to shareholders by failing to conduct a fair process and whether Novartis is underpaying for the Company.
NEW YORK, Dec. 10, 2019 -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: The Medicines Company (NASDAQ: MDCO)The.
NEW YORK, NY / ACCESSWIRE / December 9, 2019 / The following statement is being issued by Levi & Korsinsky, LLP: Levi & Korsinsky, LLP announces that investigations have commenced on behalf of shareholders ...
NEW YORK, NY / ACCESSWIRE / DECEMBER 5, 2019 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New ...